Aim: Most statins increase the risk of new-onset diabetes. Unlike other statins, pitavastatin is reported to exert neutral effects on serum glucose level, but the precise mechanism is unknown. Methods: Eight-week-old male C57BL/6J mice (n=26) were fed high-fat diet (HFD, 45% fat) with 0.01% pla-cebo, rosuvastatin, or pitavastatin for 12 weeks. Cultured HepG2, C2C12, and 3T3-L1 cells and visceral adipo-cytes from HFD-fed mice were treated with vehicle or 10 µM statins for 24 h. The effects of pitavastatin and rosuvastatin on intracellular insulin signaling and glucose transporter 4 (GLUT4) translocation were evaluated. Results: After 12 weeks, the fasting blood glucose level was significantly lower in pitavastatin-treated group than in rosuvastatin-treated group (115.2±7.0 versus 137.4±22.3 mg/dL, p=0.024). Insulin tolerance significantly improved in pitavastatin-treated group as compared with rosuvastatin-treated group, and no significant difference was observed in glucose tolerance. Although plasma adiponectin and insulin levels were not different between the two statin treatment groups, the insulin-induced protein kinase B phosphorylation was weakly attenuated in pitavastatin-treated adipocytes than in rosuvastatin-treated adipocytes. Furthermore, minor attenu-ation in insulin-induced GLUT4 translocation to the plasma membrane of adipocytes was observed in pitavas-tatin-treated group. Conclusion: Pitavastatin showed lower diabetogenic effects than rosuvastatin in mice that may be mediated by minor attenuations in insulin signaling in adipocytes.
|Number of pages||12|
|Journal||Journal of atherosclerosis and thrombosis|
|Publication status||Published - 2020|
Bibliographical noteFunding Information:
This work was supported by a faculty research grant of Yonsei University College of Medicine (6-2017-0053) and the Bio & Medical Technology Development Program of the NRF, Korea, MSIP (2016R1A2B4013029) to E.S. Kang, and Basic Science Research Program through the NRF, Korea by the Ministry of Education (2015R1D1A10905895) to H. Lee.
© 2020 Japan Atherosclerosis Society.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Cardiology and Cardiovascular Medicine
- Biochemistry, medical